We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Biomarkers for Diabetic Kidney Disease to Improve Diagnosis and Monitoring

By LabMedica International staff writers
Posted on 08 Jan 2024

Diabetic kidney disease (DKD) is a major microvascular complication arising from type 2 diabetes mellitus (T2DM), leading to end-stage renal disease (ESRD). More...

Despite advancements in treatment options such as hyperglycemic and blood pressure control and renin-angiotensin system blockades, DKD continues to prevail at alarming rates. Clinically, DKD often progresses from microalbuminuria to macroalbuminuria, marked by increased levels of albumin in the urine and an initial hyperfiltration phase followed by a gradual decline in renal function. However, variations in clinical presentations and progression rates to ESRD have been noted in recent studies. As scientific understanding evolves, the need for specific biomarkers for DKD has become increasingly vital. Now, an analysis of urinary and exosome proteome profiling by a team of scientists has led to the discovery of biomarkers for DKD, offering the potential for early diagnosis and treatment.

The research carried out by scientists at the Chinese Academy of Sciences (Beijing, China) involved extensive urinary proteomics analysis of 144 patients and urinary exosome proteomics of 44 patients with varying degrees of albuminuria related to T2DM. Utilizing exosomes for biomarker discovery offers several benefits, including minimizing the presence of abundant proteins in urine and enriching a subproteome comprising membrane and cytosolic proteins. Urinary exosomes also provide crucial information from a wide range of epithelial origins, reflecting physiological or pathological processes in virtually all epithelial cells exposed to the urinary space. Additionally, proteomic analysis of urinary exosomes can identify proteins specifically linked to certain kidney diseases, as was the case in this study.

The study analyzed urine samples from 144 clinical patients, including 19 healthy controls and 125 DM patients. The diabetic group was further categorized into three stages based on albumin-to-creatinine ratio (ACR) values. The research highlighted the dynamic nature of urinary and exosome proteomes in T2DM patients at different albuminuria stages. Proteins were grouped into six clusters based on their expression patterns throughout DKD progression. The study observed a significant decrease in proteins associated with glycolytic and ubiquitination processes from healthy controls to early DM stages, with a gradual decrease continuing to the late DM stages. Conversely, proteins involved in lipid transport and cholesterol esterification progressively increased, peaking at the most advanced stage. Proteins involved in carbohydrate metabolic processes showed high expression in early DM patients, decreasing as DKD progressed. Additionally, the study identified and validated potential biomarkers for DKD diagnosis or disease monitoring, such as SERPINA1 and TF, in another cohort of diabetic urine samples with varying DKD degrees. Thus, this research has provided a deeper understanding of the biomarkers associated with renal disease, fueling hopes for improved early-stage treatments and management strategies for DKD.

Related Links:
Chinese Academy of Sciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Platelet Function Analyzer
PL-12
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.